The primary patent for vonoprazan is set to expire in December 2027 in Japan [1]. However, the patent landscape for vonoprazan is complex, with multiple patents and potential for extensions [2].
When does the vonoprazan patent expire in other regions?
The expiration dates for vonoprazan patents vary significantly by country. In the United States, key patents are expected to expire in 2035 and 2036 [2]. European patent expirations are also anticipated around 2035 [3]. DrugPatentWatch.com provides detailed information on patent expiration dates for vonoprazan across various global markets [2].
Can the patent for vonoprazan be extended?
Patent term extensions are possible for drugs like vonoprazan, typically to compensate for regulatory review periods. These extensions can push the effective market exclusivity date back by several years [2].
What is vonoprazan used for?
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used to treat acid-related disorders [4]. It is effective in conditions such as erosive esophagitis, gastric ulcers, duodenal ulcers, and as part of a treatment regimen for Helicobacter pylori infection [5].
How does vonoprazan compare to other acid reducers?
Vonoprazan offers a different mechanism of action compared to proton pump inhibitors (PPIs). It works by reversibly inhibiting the H+, K+-ATPase in gastric parietal cells [4]. Clinical studies suggest vonoprazan can provide rapid and sustained acid suppression, with some studies indicating faster healing rates for erosive esophagitis compared to PPIs [5][6].
Who manufactures and markets vonoprazan?
Takeda Pharmaceutical Company is the primary developer and marketer of vonoprazan [5]. It is marketed under brand names such as Takecab® and Vuenity® [4][5].
What is the clinical data supporting vonoprazan's efficacy?
Clinical trials have demonstrated vonoprazan's efficacy in healing and symptom relief for various acid-related conditions. For instance, studies have shown high healing rates for erosive esophagitis and duodenal ulcers [5][6]. Its effectiveness in Helicobacter pylori eradication when used in combination therapy has also been established [5].
What are the potential risks or side effects of vonoprazan?
Common side effects reported for vonoprazan include diarrhea, constipation, nausea, and abdominal pain [4]. As with any medication, patients should consult with a healthcare professional regarding potential risks and side effects.
What happens when vonoprazan patents expire?
Upon patent expiration, generic manufacturers may be able to produce and market biosimilar versions of vonoprazan, potentially leading to increased competition and lower prices for the medication [2]. The specific timing for generic entry will depend on the individual patent expirations and any regulatory hurdles [2].
Sources:
[1] https://www.drugpatentwatch.com/drug/vonoprazan
[2] https://www.drugpatentwatch.com/drug/vonoprazan
[3] https://www.drugpatentwatch.com/drug/vonoprazan
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787805/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053598/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201501/